MedTrace Logo

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

NCT00035035 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2006-07-19

No results posted yet for this study

Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Conditions

  • Pancreatic Neoplasms
  • Metastases, Neoplasm

Interventions

DRUG

GEMZAR

DRUG

ALIMTA

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Colombia
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Peru
  • Portugal
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00035035 on ClinicalTrials.gov